Cancer Research and Treatment

The Korean Cancer Association (대한암학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathological and Immunohistochemical Features of Gastointestinal Stromal Tumors

  • Kang, Yu-Na (Department of Pathology, Keimyung University School of Medicine) ;
  • Jung, Hye-Ra (Department of Pathology, Keimyung University School of Medicine) ;
  • Hwang, Il-Seon (Department of Pathology, Keimyung University School of Medicine)
  • Received : 2010.01.12
  • Accepted : 2010.02.02
  • Published : 2010.09.30
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to evaluate the clinicopathological features and immunohistochemical features of gastrointestinal stromal tumor (GIST), and specifically the expressions of platelet derived growth factor receptor A (PDGFRA), protein kinase C theta (PKC theta), discovered on GIST-1 (DOG-1), p16 and p27. Materials and Methods: Total 118 patients who underwent surgical resection for GIST at our institution between Jan 1997 and Dec 2007 were retrospectively studied. Immunohistochemical staining for c-kit, PDGFRA, PKC-theta, DOG-1, p16 and p27 was performed on a tissue microarray of the 118 GIST. The clinicopathologic parameters, the disease-free survival (DFS) and the overall survival rate were analyzed along with immunohistochemistry. Results: The immunohistochemical stains for c-kit, CD34, PKC-theta, PDGFRA, DOG-1, p16 and p27 were positive in 89.8%, 72.0%, 56.8%, 94.9%, 90.7%, 69.5% and 44.1% of the tumor samples, respectively. The immunohistochemical expression of c-kit was strongly correlated with PKC-theta (p=0.000), DOG-1 (p=0.000) and CD34 (p=0.002). The DFS rate was significantly decreased for the patients with peritoneal GIST, high risk GIST, $\geq10$ cm-sized GIST, $\geq10$ mitoses/50 high power fields (HPFs) and p16 positivity (p=0.001, p=0.004, p=0.001, p=0.003 and p=0.028). GISTs $\geq10$ cm, epithelioid tumor cell type, and c-kit, and DOG-1 negativity were significantly associated with shorter period of overall survival (p=0.048, p=0.006, p=0.000 and p=0.000). Conclusion: The expression of p16 and no expression of c-kit and DOG-1 in GISTs, as well as peritoneal tumor site, high risk group, large tumor size, epithelioid tumor cell type and numerous mitoses, may be potentially prognostic factors for predicting worse outcome for patients who suffer from GIST.

Keywords

References

  1. Connolly E, Gaffney E, Reynolds J. Gastrointestinal stromal tumours. Br J Surg. 2003;90:1178-86. https://doi.org/10.1002/bjs.4352
  2. Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley B, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10:81. https://doi.org/10.1177/106689690201000201
  3. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12. https://doi.org/10.1007/s004280000338
  4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80. https://doi.org/10.1126/science.279.5350.577
  5. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int. 2005;55:106-12. https://doi.org/10.1111/j.1440-1827.2005.01806.x
  6. Sevinc A, Camci C, Yilmaz M, Buyukhatipoglu H. The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective. Onkologie. 2007;30:645-8. https://doi.org/10.1159/000109978
  7. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2004;126:318-21. https://doi.org/10.1053/j.gastro.2003.10.079
  8. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-13. https://doi.org/10.1016/S0002-9440(10)63279-8
  9. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000;7:705-12. https://doi.org/10.1007/s10434-000-0705-6
  10. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;23:377-89. https://doi.org/10.1097/00000478-199904000-00002
  11. Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, et al. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009;11:98-102.
  12. Liu FY, Qi JP, Xu FL, Wu AP. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor. World J Gastroenterol. 2006;12:4161-5. https://doi.org/10.3748/wjg.v12.i26.4161
  13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKCtheta expression in gastrointestinal stromal tumor. Mod Pathol. 2006;19:1480-6.
  14. Isaac JC, Willmore C, Holden JA, Layfield LJ. A c-kit-negative gastrointestinal stromal tumor with a platelet-derived growth factor receptor alpha mutation. Appl Immunohistochem Mol Morphol. 2006;14:52-6. https://doi.org/10.1097/01.pai.0000156866.84350.ec
  15. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-78.
  16. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007;17:3-7. https://doi.org/10.1016/j.gde.2006.12.010
  17. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10. https://doi.org/10.1126/science.1079666
  18. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-9. https://doi.org/10.1200/JCO.2003.04.190
  19. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med Klin (Munich). 2002;97(Suppl 1):28-30.
  20. Kim T, Lee H, Kang Y, Choe M, Ryu M, Chang H, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res. 2004;10:3076. https://doi.org/10.1158/1078-0432.CCR-03-0581
  21. Huang HY, Huang WW, Lin CN, Eng HL, Li SH, Li CF, et al. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors:prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006;13:1633-44. https://doi.org/10.1245/s10434-006-9188-4
  22. Nemoto Y, Mikami T, Hana K, Kikuchi S, Kobayashi N, Watanabe M, et al. Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1. Pathol Int. 2006;56:724-31. https://doi.org/10.1111/j.1440-1827.2006.02038.x
  23. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36:828-37. https://doi.org/10.1016/j.humpath.2005.03.012
  24. Schmieder M, Wolf S, Danner B, Stoehr S, Juchems MS, Wuerl P, et al. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia. 2008;10:1154-62. https://doi.org/10.1593/neo.08646

Cited by

  1. Exon 11 mutations, Ki67, and p16INK4A as predictors of prognosis in patients with GIST vol.207, pp.11, 2010, https://doi.org/10.1016/j.prp.2011.09.008
  2. Expression of DOG1, CD117 and PDGFRA in Gastrointestinal Stromal Tumors and Correlations with Clinicopathology vol.13, pp.4, 2010, https://doi.org/10.7314/apjcp.2012.13.4.1389
  3. Deciding Laparoscopic Approaches for Wedge Resection in Gastric Submucosal Tumors: A Suggestive Flow Chart Using Three Major Determinants vol.215, pp.6, 2010, https://doi.org/10.1016/j.jamcollsurg.2012.07.009
  4. Simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) in the stomach: case report vol.10, pp.None, 2010, https://doi.org/10.1186/1477-7819-10-6
  5. Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors vol.17, pp.11, 2010, https://doi.org/10.1007/s11605-013-2243-0
  6. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours vol.48, pp.9, 2010, https://doi.org/10.3109/00365521.2013.816770
  7. Retrospective study of endoscopic submucosal tunnel dissection (ESTD) for surgical resection of esophageal leiomyoma vol.27, pp.11, 2010, https://doi.org/10.1007/s00464-013-3035-z
  8. An intra-abdominal desmoid tumor difficult to distinguish from a gastrointestinal stromal tumor: report of two cases vol.44, pp.11, 2010, https://doi.org/10.1007/s00595-013-0681-7
  9. Endoscopic full-thickness resection for gastric submucosal tumors arising from the muscularis propria layer. vol.20, pp.38, 2014, https://doi.org/10.3748/wjg.v20.i38.13981
  10. Compound gastroenteropancreatic neuroendocrine and gastrointestinal stromal tumors in the stomach: A case report vol.10, pp.5, 2010, https://doi.org/10.3892/ol.2015.3666
  11. Does Immunohistochemistry for Discovered on GIST1 and Minichromosome Maintenance Protein7 Provide Additional Clinicopathological Value in Gastrointestinal Stromal Tumors? vol.6, pp.3, 2010, https://doi.org/10.14740/wjon918w
  12. Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours – an analysis of 70 cases from 2004 to 2010 vol.11, pp.2, 2010, https://doi.org/10.5114/pg.2015.52587
  13. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations vol.16, pp.None, 2010, https://doi.org/10.1186/s12885-016-2111-x
  14. PKCθ utility in diagnosing c-KIT/DOG-1 double negative gastrointestinal stromal tumors vol.8, pp.34, 2010, https://doi.org/10.18632/oncotarget.19116
  15. Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients vol.9, pp.25, 2018, https://doi.org/10.18632/oncotarget.24799
  16. Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis vol.16, pp.None, 2010, https://doi.org/10.1186/s12957-018-1532-1
  17. Gastrointestinal stromal tumor of the excluded stomach after Roux-en-Y gastric bypass: A case report and literature review vol.74, pp.None, 2010, https://doi.org/10.1016/j.ijscr.2020.08.026
  18. DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples vol.228, pp.None, 2021, https://doi.org/10.1016/j.prp.2021.153663